Back to Search
Start Over
Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial
- Source :
- Acta Neuropathologica, 123(6), 841-852. Springer Verlag, Acta Neuropathologica, 123, 841-52, Acta Neuropathologica, 123(6), 841-852. Springer-Verlag, Hegi, M E, Janzer, R C, Lambiv, W L, Gorlia, T, Kouwenhoven, M C, Hartmann, C, von Deimling, A, Martinet, D, Besuchet Schmutz, N, Diserens, A C, Hamou, M F, Bady, P, Weller, M, van den Bent, M J, Mason, W P, Mirimanoff, R O, Stupp, R, Mokhtari, K & Wesseling, P 2012, ' Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial ', Acta Neuropathologica, vol. 123, no. 6, pp. 841-852 . https://doi.org/10.1007/s00401-011-0938-4, Acta Neuropathologica, 123, 6, pp. 841-52, Acta neuropathologica, Acta Neuropathologica, vol. 123, no. 6, pp. 841-852
- Publication Year :
- 2012
-
Abstract
- Item does not contain fulltext Glioblastoma (GBM) is a morphologically heterogeneous tumor type with a median survival of only 15 months in clinical trial populations. However, survival varies greatly among patients. As part of a central pathology review, we addressed the question if patients with GBM displaying distinct morphologic features respond differently to combined chemo-radiotherapy with temozolomide. Morphologic features were systematically recorded for 360 cases with particular focus on the presence of an oligodendroglioma-like component and respective correlations with outcome and relevant molecular markers. GBM with an oligodendroglioma-like component (GBM-O) represented 15% of all confirmed GBM (52/339) and was not associated with a more favorable outcome. GBM-O encompassed a pathogenetically heterogeneous group, significantly enriched for IDH1 mutations (19 vs. 3%, p = 0.003) and EGFR amplifications (71 vs. 48%, p = 0.04) compared with other GBM, while co-deletion of 1p/19q was found in only one case and the MGMT methylation frequency was alike (47 vs. 46%). Expression profiles classified most of the GBM-O into two subtypes, 36% (5/14 evaluable) as proneural and 43% as classical GBM. The detection of pseudo-palisading necrosis (PPN) was associated with benefit from chemotherapy (p = 0.0002), while no such effect was present in the absence of PPN (p = 0.86). In the adjusted interaction model including clinical prognostic factors and MGMT status, PPN was borderline nonsignificant (p = 0.063). Taken together, recognition of an oligodendroglioma-like component in an otherwise classic GBM identifies a pathogenetically mixed group without prognostic significance. However, the presence of PPN may indicate biological features of clinical relevance for further improvement of therapy. 01 juni 2012
- Subjects :
- Male
Oncology
Pathology
medicine.medical_treatment
2804 Cellular and Molecular Neuroscience
Central Pathology Review
0302 clinical medicine
Brain Neoplasms
Chemoradiotherapy
Middle Aged
Prognosis
Translational research Tissue engineering and pathology [ONCOL 3]
3. Good health
Dacarbazine
ErbB Receptors
Treatment Outcome
2728 Neurology (clinical)
030220 oncology & carcinogenesis
Female
medicine.drug
Adult
medicine.medical_specialty
IDH1
Adolescent
Oligodendroglioma
610 Medicine & health
Pathology and Forensic Medicine
Young Adult
03 medical and health sciences
Cellular and Molecular Neuroscience
Internal medicine
Temozolomide
medicine
Humans
Clinical significance
Aged
Brain Neoplasms/genetics
Brain Neoplasms/pathology
Clinical Trials, Phase III as Topic
DNA Methylation
Dacarbazine/analogs & derivatives
Dacarbazine/therapeutic use
Glioblastoma/genetics
Glioblastoma/pathology
Mutation
Oligodendroglioma/genetics
Oligodendroglioma/pathology
Receptor, Epidermal Growth Factor/genetics
Receptor, Epidermal Growth Factor/metabolism
Survival Analysis
Chemotherapy
business.industry
medicine.disease
10040 Clinic for Neurology
nervous system diseases
2734 Pathology and Forensic Medicine
Clinical trial
Component (group theory)
Neurology (clinical)
Glioblastoma
business
030217 neurology & neurosurgery
Subjects
Details
- ISSN :
- 00016322
- Volume :
- 123
- Database :
- OpenAIRE
- Journal :
- Acta Neuropathologica
- Accession number :
- edsair.doi.dedup.....e1a5a1d3c56b8ef520162e875697e9dd
- Full Text :
- https://doi.org/10.1007/s00401-011-0938-4